A clinical trial update dated October 30, 2026 lists a Phase 2 study titled "The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)" as currently recruiting. The study is registered under identifier NCT07855692 on ClinicalTrials.gov.
Nesiritide remains classified as an unapproved research compound and is not described as part of this trial's interventions in the available data. No outcome data, results, or efficacy claims are included in this update. The listed status reflects only that participant recruitment is underway as of the date given.
This record provides phase and status information only, as reported in the trial registry. No additional details about trial design, endpoints, or enrollment numbers were provided in the source event data. Readers should treat this as a recruitment status update rather than a report of clinical findings.
For broader context on nesiritide, including its regulatory status and general background, readers can consult the compound overview.